La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zealand Pharma Croissance future

Future contrôle des critères 2/6

Zealand Pharma devrait augmenter ses bénéfices et son chiffre d'affaires de 20.7% et de 33.9% par an respectivement. Le BPA devrait croître de de 26.9% par an. Le rendement des capitaux propres devrait être 1.6% dans 3 ans.

Informations clés

20.7%

Taux de croissance des bénéfices

26.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	36.6%
Taux de croissance des recettes	35.0%
Rendement futur des capitaux propres	1.6%
Couverture par les analystes	Good
Dernière mise à jour	19 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

LSE:0NZU - Estimations futures des analystes et données financières antérieures (DKK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1,580	-502	352	-5	7
12/31/2025	1,010	-581	186	-616	8
12/31/2024	466	-746	-138	-649	7
6/30/2024	368	-712	-538	-508	N/A
3/31/2024	344	-739	-479	-453	N/A
12/31/2023	343	-704	-449	-426	N/A
9/30/2023	343	-760	-778	-758	N/A
6/30/2023	92	-986	-782	-771	N/A
3/31/2023	107	-1,064	-831	-822	N/A
12/31/2022	104	-966	-954	-942	N/A
9/30/2022	93	-855	-999	-978	N/A
6/30/2022	104	-845	-1,083	-1,060	N/A
3/31/2022	114	-608	-1,182	-1,161	N/A
12/31/2021	109	-755	-1,234	-1,212	N/A
9/30/2021	158	-925	-1,183	-1,181	N/A
6/30/2021	161	-1,012	-1,085	-1,071	N/A
3/31/2021	347	-909	-870	-844	N/A
12/31/2020	192	-669	-714	-689	N/A
9/30/2020	301	-660	-618	-580	N/A
6/30/2020	255	-545	-670	-632	N/A
3/31/2020	54	-624	-698	-671	N/A
12/31/2019	41	-572	-433	-409	N/A
9/30/2019	43	-508	-408	-391	N/A
6/30/2019	33	524	927	-346	N/A
3/31/2019	28	551	952	-320	N/A
12/31/2018	38	581	810	-461	N/A
9/30/2018	35	601	853	-417	N/A
6/30/2018	74	-361	-317	-310	N/A
3/31/2018	68	-346	N/A	-320	N/A
12/31/2017	136	-274	N/A	-279	N/A
9/30/2017	306	-112	N/A	-64	N/A
6/30/2017	307	-100	N/A	-113	N/A
3/31/2017	306	-102	N/A	-52	N/A
12/31/2016	231	-157	N/A	41	N/A
9/30/2016	221	-138	N/A	-114	N/A
6/30/2016	189	-158	N/A	-128	N/A
3/31/2016	188	-139	N/A	-120	N/A
12/31/2015	188	-114	N/A	-225	N/A
9/30/2015	27	-246	N/A	-216	N/A
6/30/2015	78	-178	N/A	-149	N/A
3/31/2015	75	-147	N/A	-146	N/A
12/31/2014	154	-65	N/A	-42	N/A
9/30/2014	151	-47	N/A	-50	N/A
6/30/2014	95	-98	N/A	-100	N/A
3/31/2014	92	-97	N/A	-85	N/A
12/31/2013	7	-184	N/A	-170	N/A
9/30/2013	3	-191	N/A	-134	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 0NZU devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 0NZU devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 0NZU devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 0NZU ( 33.9% par an) devrait croître plus rapidement que le marché UK ( 3.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 0NZU ( 33.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 0NZU devrait être faible dans 3 ans ( 1.6 %).

Zealand Pharma Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Recent updates

President & CEO recently sold kr.31m worth of stock

Second quarter 2024 earnings released: kr.4.67 loss per share (vs kr.5.50 loss in 2Q 2023)

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: kr.192

New 90-day low: kr.202

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Third quarter 2020 earnings released: kr.5.76 loss per share

Revenue misses expectations

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day low: kr.211

New 90-day high: kr.245

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - kr.220

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance